We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs, Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » Drugs » Postmarket Safety

Postmarket Safety
Postmarket Safety RSS Feed RSS

Pfizer Canada Recalls Accuretic Blood Pressure Tablets

March 7, 2022
Currently, Accuretic hasn’t been recalled in the U.S. Read More

Large Study Confirms Blood Clots Are Rare After AstraZeneca-Oxford COVID-19 Vaccine

February 24, 2022
Blood clots occurred only after the first dose, the study found. Read More

EMA Lists Rare Spinal Condition as Side Effect of AstraZeneca’s COVID-19 Shot

January 18, 2022
The EMA previously recommended adding transverse myelitis to the list of possible side effects linked with Johnson & Johnson’s COVID-19 vaccine. Read More

EMA Launches Review of Liver Disease Drugs Containing Terlipressin

January 18, 2022
Terlipressin products are authorized in several EU countries to treat increased pressure in central veins that can cause kidney problems in people with hepatorenal syndrome. Read More

FDA Warning: Buprenorphine to Treat Opioid Use Disorder Can Cause Dental Problems

January 14, 2022
The FDA has issued a warning about the potential for serious dental problems associated with buprenorphine medicines dissolved in the mouth to treat opioid use disorder (OUD) and pain. Read More

Viona Recalls 33 Lots of Diabetes Drug Due to Possible NMDA Contamination

January 4, 2022
But the FDA warned that patients shouldn’t discontinue taking metformin without first consulting with a doctor. Read More

FDA Places Hold on Gilead’s Injectable HIV Drug Over Possible Glass Contaminants

December 23, 2021
The FDA has put a clinical hold on Gilead Sciences’ injectable HIV drug lenacapavir because of the risk of glass particles from the vials getting into the medication. Read More

Lupin Recalls Subpotent Generic Oral Contraceptives

December 14, 2021
In October, Lupin recalled all batches of its irbesartan and irbesartan/hydrochlorothiazide tablets supplied in the U.S. Read More

Gilead Sciences Recalls Remdesivir Lots Over Glass Particulates

December 7, 2021
Gilead Sciences has recalled two lots of its blockbuster COVID-19 antiviral Veklury (remdesivir) for possible contamination with glass particulates. Read More

Indian Generics Maker Sun Pharma Recalls ED Meds in the U.S.

November 24, 2021
The problem lots were made in India and shipped to one distributor in the U.S. that "may have” further released the product nationwide, the FDA said. Read More

Judge Gives Green Light for Claims Over Merck’s Shingles Vaccine

November 17, 2021
The case is just one of thousands of multidistrict complaints in recent years charging Merck with selling an unsafe shingles shot. Read More

Moderna Admits COVID-19 Shot Is Linked to Myocarditis

November 16, 2021
The company maintains that the shot’s upsides continue to outweigh the rare risk of myocarditis. Read More
Previous 1 2 3 4 5 6 7 8 9 … 81 82 Next

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Advamedica’s Hemostat Cleared for Severe Surgical Bleeding

  • FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation

  • Wesper Next-Generation Device Cleared for Sleep Test Data Collection

  • FDA Approves First-Ever Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing